Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.

Paczkowski FA, Sharpe IA, Dutertre S, Lewis RJ.

J Biol Chem. 2007 Jun 15;282(24):17837-44. Epub 2007 Apr 11.

2.

Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT).

Bryan-Lluka LJ, Papacostas MH, Paczkowski FA, Wanstall JC.

Br J Pharmacol. 2004 Sep;143(1):63-70. Epub 2004 Aug 9.

3.
4.

Functional significance of a highly conserved glutamate residue of the human noradrenaline transporter.

Sucic S, Paczkowski FA, Runkel F, Bönisch H, Bryan-Lluka LJ.

J Neurochem. 2002 Apr;81(2):344-54.

5.

Amino acids involved in differences in the pharmacological profiles of the rat and human noradrenaline transporters.

Paczkowski FA, Bryan-Lluka LJ.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Apr;365(4):312-7. Epub 2002 Feb 20.

PMID:
11919656
6.

Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.

Paczkowski FA, Bönisch H, Bryan-Lluka LJ.

Pharmacogenetics. 2002 Mar;12(2):165-73.

PMID:
11875370
7.

Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.

Paczkowski FA, Bryan-Lluka LJ.

Brain Res Mol Brain Res. 2001 Dec 16;97(1):32-42.

PMID:
11744160
8.

Effects of short- and long-term exposure to c-AMP and c-GMP on the noradrenaline transporter.

Bryan-Lluka LJ, Paczkowski FA, Bönisch H.

Neuropharmacology. 2001 Mar;40(4):607-17.

PMID:
11249970
9.

Comparison of the pharmacological properties of cloned rat, human, and bovine norepinephrine transporters.

Paczkowski FA, Bryan-Lluka LJ, Pörzgen P, Brüss M, Bönisch H.

J Pharmacol Exp Ther. 1999 Aug;290(2):761-7.

PMID:
10411589

Supplemental Content

Loading ...
Support Center